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Prevention and cure of type 2 diabetes
General practitioners are treating more
cases of diabetes
Editor—Most studies measuring the preva›
lence of diabetes have been carried out in
one locality and have generally measured
point prevalences. Hence, although the
prevalence of diabetes in England and Wales
is increasing,1 time trend data on prevalence
and future projections based on sound data
are both lacking. We recently estimated the
prevalence of diabetes in England and Wales
between 1994 and 1998 using data from 210
general practices with a combined list size of
1.2 million.2
We found that the overall prevalence of
diabetes during this period increased from
1.99% to 2.43% in males and from 1.69% to
2.04% in females. This striking increase in
the prevalence of diabetes in primary care is
likely to be due to a combination of factors,
including better case ascertainment, rising
rates of obesity, an ageing population, and
an increase in both the size and average age
of the ethnic minority population. Overall,
29%, 48%, and 24% of males with diabetes
and 26%, 48%, and 26% of females with
diabetes were treated by diet, oral hypogly›
caemic drugs alone, and insulin respectively.
We estimated around 1.15 million
people had a diagnosis of diabetes mellitus
in England and Wales in 1998. If the age
specific prevalence of diabetes increases by a
modest 30% over the next 25 years (less than
predicted by many authorities), then the
number of people with diabetes will increase
by 70%, to 1.96 million by 2023. If age
specific prevalence increases by more than
30%, then the increase in the number of
cases will be even larger.
Our findings illustrate the potential size
of the diabetes epidemic facing England and
Wales. The epidemic will have major
implications for the NHS, which will have to
provide diabetic services for these patients,
as well as deal with the clinical and
psychosocial complications resulting from
diabetes. We therefore reinforce the need to
tackle the underlying causes of this epi›
demic, particularly by increasing levels of
physical activity and reducing rates of
obesity in our society.3
Azeem Majeed professor of primary care
University College London, London WC1H 9QU
a.majeed@ucl.ac.uk
Angela Newnham senior lecturer in public health
medicine
Thames Cancer Registry, King’s College, London
SE1 3QD
Ronan Ryan research officer
Office for National Statistics, London SW1V 2QQ
Kamlesh Khunti senior lecturer in general practice
Department of General Practice, University of
Leicester, Leicester LE5 4PW
1 Pinkney J. Prevention and cure of type 2 diabetes. BMJ
2002;325:232›3. (3 August.)
2 Newnham A, Ryan R, Khunti K, Majeed A. Prevalence of
diagnosed diabetes mellitus in general practice in England
and Wales, 1994 to 1998. Health Stat Q 2002;14:5›13.
(www.azmaj.org/PDF/Diabetes.pdf (accessed 16 October
2002).)
3 Dr Curran and Partners. Staying healthy. How to stay
healthy. Available at: www.claphamhealth.org.uk/
Healthy.htm (accessed 16 October 2002).
Let’s move upstream to obesogenic
environments, please
Editor—Another BMJ brings yet another
editorial on obesity and associated diabetes.1
Once again there is no reference to the
real cause of this problem—obesogenic
environments.
Why is it that commentators constantly
shy away from digging deeper? Why do they
repeatedly refuse to venture upstream? It
must be blindingly obvious to everyone by
now that there is, and never will be, any con›
ventional medical treatment for obesity or
diabetes. Doctors should come clean and tell
patients and populations that the cure lies
not with medicine but in how our societies
are created.
Children are denied vital play space
because politicians favour selling play space
to developers. Sixty per cent of the green
space used for housing in London in the
past 10 years came from the sale of playing
fields (Open spaces conference, Bankside
Trust, London, March 2002). We exclude
children’s play from our streets by permit›
ting a 30 mph urban speed limit. If we are to
encourage an extra 3 miles of walking daily
to enable 4 kg weight loss, reducing the risk
of developing diabetes by 58%, then we must
create an environment where people are
able to walk. It is facile and cruel just to tell
people that they must walk more. Healthy
people need healthy environments.
Politicians have the central role in creat›
ing healthy populations. They should stop
pandering to powerful lobbies such as the
pharmaceutical, motoring, food, and
tobacco industries. If we as doctors do not
tell them that they have the prime responsi›
bility for health then they will continue to
abuse us by heaping us with impossible
responsibilities for changing the health of
our nation. When we inevitably fail then
they will give us the blame.
General practice in the United Kingdom
is currently teetering on the brink of such
stupidity in the shape of a new medical
contract that will enslave us into performing
the impossible tasks of reducing blood
pressure/weight/glycated haemoglobin con›
centrations/cholesterol concentrations, etc.
We will soon be shackled to tick box medical
consultations stuffing irrelevant data into
computers in a pointless and ever increasing
spiral of ineffectual intervention while the
good that we can do, but which has never
been recognised or rewarded, will simply
wither and die.
Perhaps the next obesity and diabetes
editorial should be commissioned from a
sociologist?
Colin Guthrie general practitioner
1448 Dumbarton Road, Glasgow G14 9DW
grey_triker@hotmail.com
1 Pinkney J. Prevention and cure of type 2 diabetes. BMJ
2002;325:232›3. (3 August.)
Many South Asian people
probably need pre›diabetes care
Editor—In their editorial Venkat Narayan et
al make a case for the American Diabetes
Association’s recommendation to screen for
pre›diabetes in people over 45.1 Pre›diabetes
is defined as either impaired glucose toler›
ance (two hour glucose concentration 7.8›
11 mmol/l after a glucose load) or an
impaired fasting glucose concentration of
6.1›6.9 mmol/l. Those screening positive are
at high risk of cardiovascular diseases and
diabetes and therefore would be counselled
on weight loss and increasing physical activity.
This recommendation has profound
implications for the health care of South
Asian populations originating in the Indian
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subcontinent living in urban settings where
pre›diabetes is common.2
We reported a secondary analysis of the
Newcastle heart project based on age and sex
adjustment using the standard population of
England and Wales on the prevalence of
diabetes and pre›diabetes in those aged
25›74 of South Asian (n=680), Chinese
(n=375), and white European origin (n=824).
Weighted percentages and unweighted num›
bers for South Asians show that the
prevalence of impaired fasting glucose (138/
680) and impaired glucose tolerance
(140/680) was 19%.3 The prevalence of
pre›diabetes on either definition was 30.5%
(226/680). The prevalence of diabetes based
on two hour glucose measures was 20.1%
(160/680); on the American criteria, 21.4%
(173/680); and on either, 23.4% (189/680).
Only 49% (295/680) of the population had
normal glucose tolerance. A programme of
care for pre›diabetes would be needed for
about half of the South Asian population in
the 25›74 age group, a formidable task
complicated by issues discussed below.
Narayan et al would prioritise screening
in those with a body mass index of 25 or
more, a marker of excess adipose tissue.
Markers of obesity, including body mass
index, do not have equivalence across ethnic
groups.4 South Asians in the United
Kingdom have slightly lower indices but
higher waist:hip ratios and greater skinfold
thicknesses. Body mass index is not a good
indicator of adiposity in South Asians, and a
lower cut›off point for being overweight is
necessary.
If interventions are to work people need
to perceive risk and benefits accurately. In
the Newcastle heart project, South Asian
women’s perceptions of their own weight
did not match guidelines on being over›
weight and obese.5 A substantial proportion
of overweight South Asian women per›
ceived themselves to be of normal weight,
but women of European origin had the
opposite problem. South Asians’ knowledge
of the causation and prevention of diabetes
and heart disease in nearby South Tyneside
was poor.
Finally, lack of physical exercise poses
a huge challenge (reference available
at bmj.com/cgi/eletters/325/7361/403[
25585). Although the task of halting the
process of pre›diabetes becoming diabetes is
urgent, careful evaluation of screening and
interventions is essential.
R Bhopal Bruce and John Usher professor of public
health
C M Fischbacher clinical research fellow
Division of Community Health Sciences (Public
Health Sciences), University of Edinburgh,
Edinburgh EH8 9AG
We thank Dr Nigel Unwin for helpful advice in
preparing this letter.
1 Venkat Narayan KM, Imperatore G, Benjamin SM, Engel›
gau MM. Targeting people with pre›diabetes. BMJ
2002;325:403›4. (24 August.)
2 Bhopal RS, Unwin N, White M, Yallop J, Walker L, Alberti
KGMM, et al. Heterogeneity of coronary heart disease risk
factors in Indian, Pakistani, Bangladeshi, and European
origin populations: cross sectional study. BMJ
1999;319:215›20.
3 Unwin N, Alberti KGMM, Bhopal R, Harland J, Watson W,
White M. Comparison of the current WHO and the new
ADA criteria for the diagnosis of diabetes in three ethnic
groups in the UK. Diabet Med 1998;15:554›7.
4 Patel S, Unwin N, Bhopal R, White M, Harland J, Ayis, SA,
et al. A comparison of proxy measures of abdominal obes›
ity in Chinese, European and South Asian adults. Diabet
Med 1999;16:853›60.
5 Patel S, Bhopal R, Unwin N, White M, Alberti KG, Yallop J.
Mismatch between perceived and actual overweight in dia›
betic and non›diabetic populations: a comparative study of
South Asian and European women. J Epidemiol Community
Health 2001;55:332›3.
Women with gestational
diabetes should be targeted to
reduce cardiovascular risk
Editor—Sattar and Greer discuss the prob›
ability that complications in pregnancy may
predispose women to vascular and metabolic
disease in later life.1 The link between
pregnancy complications and coronary heart
disease remains unexplained. We believe that
during pregnancy the hormonal and other
stresses provoke cardiovascular and meta›
bolic abnormalities in susceptible individuals,
which may recur and become permanent as
the patient ages. Many of these are coronary
risk factors; disturbances in glucose metabo›
lism, which underlie the development of
gestational diabetes, are a good example.
An uncomplicated pregnancy is charac›
terised by obvious changes in lipid metabo›
lism early in pregnancy.2 These include the
formation of small, dense subfractions of
low density lipoprotein, an important risk
factor for atherosclerosis.3 These are
retained in the arterial intima, are more
easily oxidised, and once oxidised are
rapidly taken up into macrophages, creating
foam cells and atherosclerotic plaques. The
additional effect of pregnancy on lipid
metabolism in people with diabetes and
those at increased risk of developing
diabetes may markedly increase cardiovas›
cular risk in these women.
We recently studied three groups of
pregnant women: healthy controls (n=17,
mean age 29.2 (SD 1.1 years)), women with
type 2 diabetes (n=12, mean age 32.5 (1.6)
years), and women with gestational diabetes
mellitus (n=12, mean age 32.8 (1.5) years).
Venous blood was taken during each
trimester (first, 1›13 weeks; second, 14›27
weeks; and third, 28 weeks to term).
Samples were analysed for subfractions of
low density lipoprotein (polyacrylamide gel
electrophoresis) and triglycerides. A score
for low density lipoprotein was calculated
from the area under the curve for each sub›
fraction; the higher the score the smaller,
denser and more atherogenic the low
density lipoprotein particles.4
Triglyceride concentrations increased
throughout pregnancy in all groups. This
was most obvious during the second trimes›
ter in women with gestational diabetes
(figure). Low density lipoprotein score
progressively increased throughout preg›
nancy, implying the formation of potentially
atherogenic lipoproteins. These changes
were exaggerated in women with type 2
diabetes but more particularly in those with
gestational diabetes (figure).
We found that pregnancy and diabetes
have an additive effect on the development
of an atherogenic lipid profile. Importantly,
this is exaggerated earlier in pregnancy in
gestational diabetes. This finding may
identify women who are particularly suscep›
tible to the premature development of
atherosclerosis. We agree with Sattar and
Greer that women with gestational diabetes
should be targeted during and after preg›
nancy with advice on diet and lifestyle to try
to modify this excess cardiovascular risk.
V Toescu research associate
v.toescu@bham.ac.uk
S L Nuttall postdoctoral fellow
M J Kendall
professor of clinical pharmacology
U Martin senior lecturer in pharmacology
F Dunne senior lecturer in medicine
Division of Medical Sciences, Queen Elizabeth
Hospital, Birmingham B15 2TH
1 Sattar N, Greer IA. Pregnancy complications and maternal
cardiovascular risk: opportunities for intervention and
screening? BMJ 2002;325:157›60. (20 July.)
2 Toescu V, Nuttall SL, Martin U, Kendall MJ, Dunne F. Oxi›
dative stress in normal pregnancy. Clin Endocrinol 2002 (in
press).
3 Musliner TA, Krauss RM. Lipoprotein subspecies and risk
of coronary disease. Clin Chem 1988;34:B78›83.
4 Rajman I, Kendall MJ, Cramb R, Holder RL, Salih M,
Gammage MD. Investigation of low density lipoprotein
subfractions as a coronary risk factor in normotriglyceri›
daemic men. Atherosclerosis 1996;125:231›42.
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The global response to mental
illness
First line care facilities and support for
providers have to be improved
Editor—Thornicroft and Maingay high›
light the inadequacy of international
responses to mental illness.1 In low income
countries the burden of mental illness is
amplified by financial insecurity, poverty,
and partition of families, if not by violence
and war. Prevention in mental health is inti›
mately linked with overall human develop›
ment. Individual care is also necessary. In
some societies religious or traditional
healers still provide culturally relevant and
socially acceptable responses to problems
labelled as mental illness. Nevertheless,
mental suffering is manifest among users of
modern medical services, where it goes
largely unrecognised.
Besides poor availability of drugs,
human resources are of utmost importance
in understanding the apparent neglect of
mental health problems. Doctors and
nurses in low income countries are often
described as rude to their patients,2 partly
because they have low salaries and poor
professional perspectives, which affects
their morale, self confidence, and dedica›
tion.3 Some have problems similar to those
of their patients—for example, domestic
violence or living with HIV. Some are not
prepared to face the emotional burden of
listening to patients’ suffering. Adequate
professional support is unusual, and deal›
ing with emotions is seldom valued by the
organisational culture.4
If health care in low income countries is
to be oriented towards more biopsychoso›
cial approaches, efforts have to include
improving first line care facilities and
support for providers. Well functioning first
line facilities are crucial to integrate mental
health programmes accessible to the popu›
lation. This does not rule out specialised
services, but these tend to remain concen›
trated in cities and are often of limited
accessibility financially. In the case of mental
health services, stigmatisation furthermore
limits their acceptability to potential users.
The integration of mental health pro›
grammes in first line care facilities should of
course not be detrimental to the compre›
hensive character of the service delivered.
The purpose is not to divert available
resources to serve a specific programme but
to take advantage of the existing relations
between a service and a community to
widen the scope of responses provided
locally. Health care in low income countries
is increasingly thought of as a series of verti›
cal programmes, so the need for access to
regular health care is crucial, and specific
programmes must strengthen general serv›
ices rather than weaken them. Indeed,
mental health programmes may improve
first line care. Concerns for mental health
are likely to promote listening skills, to foster
patient centred care, and to broaden the
professional identities of care providers, cur›
rently focused on biomedical issues. This
could be an important step on the way to
quality general practice adapted to social
and cultural contexts.5
Monique Van Dormael lecturer
mvd@itg.be
Jean›Pierre Unger senior lecturer
Institute of Tropical Medicine, Public Health
Department, Nationalestraat 155, 3000 Antwerp,
Belgium
1 Thornicroft G, Maingay S. The global response to mental
illness. BMJ 2002;325:608›9. (21 September.)
2 Jewkes R, Abrahams N, Mvo Z. Why do nurses abuse
patients? Reflections from South African obstetric services.
Soc Sci Med 1998;47:1781›95.
3 Segall M. Human development challenges in health care
reform. Studies in Health Services Organisation and Policy
2000;16:7›17.
4 Van Balen H, Van Dormael M. Health service profession›
als and users. Int Soc Sci J 1999;313›26.
5 Unger J›P, Van Dormael M, Criel B, Van der Vennet J, De
Munck P. A plea for an initiative to strengthen family
medicine in public health care services of developing
countries. Int J Health Serv 2002;32:799›815.
Focus on mental health means new
opportunities for developing countries
Editor—The global resources for mental
health raise two issues.1 Crisis results from
the low priority given to and the limited
resources for mental health care. However,
the focus on mental health by the World
Health Organization offers a new oppor›
tunity for developing countries to organise
mental health using current knowledge.
Developing countries have four advan›
tages: most ill people live in the community
and are cared for by family members;
families continue to feel directly responsible
for care and support, which is an advantage
in organising services; the lack of an
extensive mental health infrastructure (spe›
cialists, specialist beds, different profession›
als, etc) means that services can be organised
using community resources; and greater
acceptance of patients by the community
allows for easier community involvement in
mental health care.
Mental health care has been integrated
with primary health care in India and Iran.
In India, initiatives began in 1975 and led to
the development of a district mental health
model (1›2 million population).2 This model
has now been implemented in 25 districts
and is expected to be extended to 100
districts in the next five years (about 150
million population). In Sri Lanka, the
amount of training in psychiatry for
undergraduates (two full months) has
increased and psychiatry is now an examina›
tion subject in the final year. The family
movement is taking shape in developing
countries, and this is fostering new partner›
ships.3 Massive disasters such as the Gujurat
earthquake and the Orissa supercyclone
have led to the development of a community
based psychosocial care with community
volunteers.4 5 Similar developments are
occurring in many countries of Asia, Africa,
and South America.
The development of mental health care
faces special challenges in developing coun›
tries. These are the need for mental health
professionals to shift from a clinical to a
public health focus; the development of
training materials, case records, information
systems, and treatment guidelines; the devel›
opment of support programmes for fami›
lies; the passing of legislation to protect the
rights of mentally ill people and increase
access to mental health care; and the
availability of adequate numbers of mental
health professionals to support, supervise,
and guide the new initiatives.
In conclusion, the global situation is
a challenge to professionals to think
innovatively.
R Srinivasa Murthy professor of psychiatry
Nimhans, Box 2900, Bangalore 560029, India
murthy@nimhans.kar.nic.in
1 Thornicroft G, Maingay S. The global response to mental
illness. BMJ 2002;325:608›9. (21 September.)
2 Chisholm D, Sekar K, Kishore Kumar K, Saeed K, James S,
et al. Integration of mental health care into primary health
care. Br J Psychiatry 2000;176:581›8.
3 Srinivasa Murthy R. Community resources for mental
health care in India. Epidemiologia e Psychiatria Sociale
2000;9:89›92.
4 Srinivasa Murthy R. Disaster and mental health: role of
mental health professionals. Indian Journal of Social Work
2000;61:675›92.
5 Kishore Kumar KV, Chandrashekar CR, Choudhury P,
Parthasarathy R, Girimaji S, et al. Information manual 2.Psy›
chosocial care for community level helpers: supercyclone. Books
for Change (Unit of Action Aid Karnataka Projects), 2000.
Discontinuation of thioridazine
Risks must be balanced
Editor—Until the Committee on the Safety
of Medicines restricted the use of thiori›
dazine in 2000, it was the most widely used
antipsychotic drug in the United Kingdom,
with 50 million years of safe use by patients
worldwide. In Scotland in 1999, were
250 808 were prescriptions dispensed in
primary care (hospital data not available, but
the safety committee reports that it was the
most widely used antipsychotic drug in hos›
pitals too). This dropped to 39 177 in 2001,
according to information from the Primary
Care Information Unit in Edinburgh.
Is thioridazine safer, cheaper, and more
effective than alternative antipsychotic drug
treatments for anxiety, agitation, mania, and
hypomania? We do not have enough
evidence to answer this because thioridazine
has been widely used for 30 years—before
the days of rigorous randomised controlled
trials. Lack of evidence is not evidence of no
benefit. Conversely, there is only evidence of
a handful of adverse cardiac events, some of
which may not have been directly caused by
thioridazine or may have been due to
combination with other drugs. Although the
reported cardiac deaths are lamentable, it
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seems that thioridazine is much safer than
other effective drugs such as aspirin, which
continues to be sold over the counter. Even
if adverse events are under›reported, there is
far more practical evidence of long term
safety for thioridazine compared with much
more expensive and much less tried and
tested drugs. A recent study noted that many
new drugs have a high rate of serious side
effects which go undetected until late in
postmarketing surveillance.2 The Com›
mittee for the Safety of Medicines needs to
balance these relative risks.
The manufacturers of thioridazine have
raised few objections to the restricted use of
thioridazine because it is an extremely
cheap drug, costing only a few pence
compared with newer antipsychotics that
may be up to a hundred times more expen›
sive, as well as having different and
sometimes distressing side effects. The
prescription costs of antipsychotic drugs has
risen sharply in Scotland in the past two
years.
Anecdotally, considerable numbers of
patients with hypomania, anxiety, and agita›
tion are having considerable problems in
adjusting to a change of drugs, and, as
Davies et al point out, informed consent may
be a problem.1 It would be very helpful if the
National Institute for Clinical Excellence or
Health Technology Board for Scotland
reviewed the evidence, risks, and benefits of
thioridazine, and considered more humane
guidelines for its future use. It seems quite
wrong to deprive so many patients of a well
tried drug.
Ann F Bisset medical adviser
Public Health Medicine, Information and Statistics
Division, Edinburgh EH5 3SQ
ann.bisset@virgin.net
Competing interests: None declared.
1 Davies SJC, Cooke LB, Moore AG, Potokar J. Discontinua›
tion of thioridazine in patients with learning disabilities:
balancing cardiovascular toxicity with adverse conse›
quences of changing drugs. BMJ 2002:324:1519›21.
(22 June.)
2 Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU,
Wolfe SM, Bor DH. Timing of new black box warnings and
withdrawals for prescription medications. JAMA 2002:
287:2215›20.
What happened to thioridazine?
Editor—The article by Davies raised some
important issues on discontinuation of
thioridazine in populations with learning
disability.1 We had successful withdrawal of
thioridazine in our services in Salford
district.
We looked at the following issues before
withdrawal of thioridazine:
(1) Initial diagnosis before thioridazine
was prescribed
(2) Duration and dose of treatment
(3) Review of previous psychiatric treat›
ment including attempts to reduce or stop
thioridazine.
Results indicated that 28 out of 175
patients under the care of a psychiatrist spe›
cialising in learning disability received
thioridazine. Twenty three patients received
small doses (50›100 mg) for many years. The
main indication for use was marked
challenging behaviour (12 patients). Based
on the above information, a decision was
made to gradually reduce (12 patients) or
suddenly stop thioridazine (16 patients).
As an alternative, a tranquilliser was pre›
scribed for all 28 patients. Risperidone was
the most commonly used atypical antipsy›
chotic drug because of some evidence of its
effectiveness in challenging behaviour.2 A
review of patients’ mental state three months
after the substitution of tranquillisers
indicated that twenty one patients either
remained stable or improved, and seven
patients deteriorated. These seven patients
subsequently improved, either by a change
to a different psychotropic drug or by
adjusting the dose of existing drugs. No
patient needed to restart taking thioridazine.
Review of previous psychiatric treatment
helped us to identify instances of rebound
increase in behavioural problems when
thioridazine was stopped. It also prompted us
to avoid using neuroleptics that were either
ineffective or caused unacceptable side
effects. Evidence of rebound aggression on
stopping neuroleptics was also observed by
Mos et al.3 This lead us to withdraw
thioridazine gradually in most cases.
In our opinion risk associated with the
withdrawal of thioridazine was managed
carefully and minimised by taking into
account the diagnosis, the dose and dura›
tion, and consequences of previous reduc›
tion in medication followed by a careful
strategy of either gradual reduction or
sudden stoppage with replacement of alter›
native tranquillisers in appropriate doses.
Pernia Arshad consultant in learning disability
psychiatry
sridhar777@yahoo.co.uk
Mary Morcos senior house officer in psychiatry
Baskaran Sridharan specialist registrar in psychiatry
Department of Psychological Medicine,
Meadowbrook Unit, Salford M6 8HG
Competing interests: None declared.
1 Davies SJC, Cooke LB, Moore AG, Potokar J. Discontinua›
tion of thioridazine in patients with learning disabilities:
balancing cardiovascular toxicity with adverse conse›
quences of changing drugs. BMJ 2002:324:1519›21.
(22 June.)
2 Vander Ben Borre R. Risperidone as add›on therapy in
behavioural disturbances in mental retardation: a double
blind placebo›controlled cross›over study. Acta Psychiatrica
Scandinavica 1993:87:167›71.
3 Mos J, Van Aken HH, Van Oorschot R, Olivier B. Chronic
treatment with eltoprazine does not lead to tolerance in its
anti›aggressive actions, in contrast to haloperidol. Eur
Neuropsychopharmacol 1996;6:1›7.
Temple healing
Healing temples may breed superstitions
Editor—Raguram et al report that when
patients with psychiatric disorders stay
briefly at a healing temple most of them
improve significantly.1 They describe at
length the legend of Muthuswamy and
endorse the local notion that the temple is
endowed with mysterious healing power.
This suggestion could leave unwary
patients with an unjustifiably favourable
impression that healing temples can cure
their diseases. Most Indians are deeply
religious and superstitious. In Indian villages
myths, misconceptions, blind beliefs, and
superstitions abound. Quacks and local
healers thrive on the illiteracy and igno›
rance of naive and gullible people and try to
hoodwink them into believing that they have
magic cures for their ills.
Muthuswamy temple might be an
exception, for it does not charge people who
stay there, and, more importantly, offers no
specific healing rituals. But local newspapers
and quacks may distort the conclusions of
the study by pointing out that even a
Western journal recognises—and endorses—
the hidden healing powers of Indian
temples. The news might make thousands of
people seek a cure for their chronic diseases
in temples and shrines. Even people with
potentially curable diseases may choose not
to see doctors in the hospitals but seek shel›
ter in holy places. The consequences of such
an attitude could be terrible.
History tells us that when tuberculosis
was a formidable foe in the 19th century
people thought that their best chance of
conquering the disease was residing in a
sanatorium.2 Patients and their doctors all
over the world believed that a salubrious
environment, clear mountain air, and nutri›
tious food was the best way to ensure cure.
Thousands of patients with tuberculosis
chose Switzerland as their health destina›
tion. Myths were woven around sanatori›
ums, and people who could afford it resided
in what they considered “magic mountains”
for as long as 10 years.
The sanatorium made most patients feel
better for a while, but their infection
progressed unabated and killed all of them.
Doctors and lay people took 75 years to
realise that sanatorium was a highly
expensive—and terribly ineffective—
intervention for getting rid of tuberculosis.
I think healing temples for alleviating
psychiatric disorders and magic mountains
for curing tuberculosis share one thing: a
strong placebo effect fostered by local
superstitions and traditions. Patients with
chronic and psychiatric diseases often do
not go to their doctors, but we should avoid
creating an impression among the public at
large that healing temples are capable of
restoring their health.
S P Kalantri professor of medicine
Mahatma Gandhi Institute of Medical Sciences,
Sevagram 442102, India
sp_kalantri@rediffmail.com
Muthuswamy temple
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1 Raguram R, Venkateswaran A, Ramakrishna J, Weiss MG.
Traditional community resources for mental health: a
report of temple healing from India. BMJ 2002;325:38›40.
(6 July.)
2 Reichman LB, Tanne JH. Timebomb: the global epidemic of
multi›drug resistant tuberculosis. New York: McGraw Hill
Press, 2002:20›21.
Spiritual care is important
Editor—As a senior house officer in an
acute psychiatric ward in central London, I
can understand why there was improvement
in the condition of the psychiatric patients
who resided in the Muthusamy temple in
India, as reported by Raguram et al.1 Patients
were brought into a place of “refuge” with
people similar to them, who understood
their condition. This would result in less
expressed emotion and distress and better
care of the individual, not only by relatives
but also by temple staff in a supportive, non›
threatening environment. Here people can
make sense of their mental illness. This is
good “psychosocial” psychiatric care.
How does this contrast with an acute
psychiatric ward? Patients are placed in a
busy and emotionally charged environment
with others who may be more disturbed,
usually with little support from relatives.
Relatives’ visiting rights are limited, and
patients may not have anyone to confide in.
Here there is good “biological” psychiatric
care, with emphasis on psychotropic drug
treatment.
What is the way forward? We need a
more holistic approach to inpatient psychi›
atric care to try to “heal” our patients, rather
than just treat their psychopathology. Family
members need to be fully involved. For seri›
ous mental illness, the individual’s spiritual
needs, which are important to most people,
must be looked after. The power of cultural
beliefs and spirituality is important, as seen
by belief in the healing power of the temple,
and this is largely neglected in modern psy›
chiatry.2 The result is increased stigmatisa›
tion of psychiatric wards, which are viewed
more as places of containment than refuge.
What would have happened if Raguram
et al distributed psychotropic drugs to the
patients at the temple? I am sure their
condition would improve more quickly as
there would be “holistic biospychosocial
healing.” I hope for the day when psychiatric
temples, or places of worship, without
stigma and with a cultural belief of healing,
will replace psychiatric wards. Then holistic
biopsychosocial care of mental illness can
truly be achieved.
Cyrus A Abbasian senior house officer
York Clinic, Guy’s Hospital, London SE1 3RR
abbasian@hotmail.com
1 Raguram R, Venkateswaran A, Ramakrishna J, Weiss MG.
Traditional community resources for mental health: a
report of temple healing from India. BMJ 2002;325:38›40.
(6 July.)
2 Culliford L. Spiritual care and psychiatric treatment, an
introduction. Adv Psychiatr Treatment 2002;8:249›61.
Author’s reply to responses
Editor—Our study was motivated by previ›
ous clinical cultural epidemiological
research on schizophrenia in Bangalore,
India. Traditional sources of help, such as
local healers and healing temples, figured
prominently in patients’ previous help seek›
ing, which suggested that research was
needed to examine their experiences at
healing temples more closely.
We reported improvement in symptoms,
and these findings were as surprising to us as
to many readers of the article. But we
recognised the diversity of practices used in
various settings of traditional healing and
emphasised that benefits documented at one
site should not be generalised to all healing
temples and that our findings should not be
construed as professional endorsements of
diverse traditional healing practices.
Nevertheless, our study does indicate the
value of traditional community resources in
caring for serious, chronic mental illnesses
and shows the effect of a supportive
environment that derives its healing power
from the cultural values of the community.
Inasmuch as such environmental supports
may be lacking in many institutions for
mental health care, we should welcome—
rather than fear misuse of—such healing
contexts. Moreover, pertinent social sup›
ports and cultural influences may profitably
complement psychopharmacological and
neurophysiological frameworks that guide
effective psychiatric practice.
Larger questions about the impact of the
sociocultural context of mental health care
for people with chronic mental illness in
India also motivated our study. Policy
making and plans for community pro›
grammes should benefit from consideration
of the nature of the existing local system
which planned interventions may try to
replace or complement. For that, research
should attend to two broad aims.
Firstly, an assessment of the impact of
traditional healing is needed with reference
both to local and professional criteria, as
reported in our article.
Secondly, the cultural epidemiology of
mental health problems—with reference to
their local experience, meaning, and
behaviour—is also needed. Findings have
been presented in a thesis by Venkateswaran
(2001) and will be elaborated elsewhere.
With appreciation of growing interests
in complementary approaches to health
care, and recognising the importance of
attention to sociocultural contexts for effec›
tive community mental health planning, sci›
entific studies are both warranted and
needed. They encourage an ongoing proc›
ess of critical rethinking to ensure the
relevance of psychiatric practice locally and
to enhance the acceptance and effectiveness
of community mental health programmes.
R Raguram professor of psychiatry
Department of Psychiatry, National Institute of
Mental Health and Neurosciences, Bangalore
560 029, India
Primary prevention strategies
for cardiovascular disease
Editor—The assumptions made by Mar›
shall and Rouse in their study are too broad
and may lead to erroneous conclusions.1
Using the Framingham equation with
average values is going to stratify the
population only by age, sex, and diabetes
status. Such stratification is simplistic and
will prove only that older people and people
with diabetes are more at risk. By assuming
the subjects are non›smokers Marshall and
Rouse exclude the most important single
weighting in the Framingham calculation.
Most practices have a register of smoking
status for most of their patients, so this
should be included.
Marshall and Rouse admit that their
method may not be able to screen all of the
population, so some will lose out. By
concentrating on the oldest patients and
patients with diabetes first, it will not detect
some who have most to lose, such as 50 year
old smokers with hypercholesterolaemia
and hypertension. Adding a few extra years
to the life of a 70 year old non›smoking nor›
motensive diabetes patient may be laudable,
but just because it is easier and cheaper does
not mean that these patients should be
prioritised to be assessed first, as this
method seems to suggest.
Many of Marshall and Rouse’s other
assumptions do not fit well with the day to
day realities of general practice. Few general
practitioners would be able to stabilise anti›
hypertensive treatment with only four
prescriptions and two follow up consulta›
tions in a year. Government policy is to issue
30 days’ supply, so Marshall and Rouse
underestimate dispensing costs. Not all of
this work can or should be done by practice
nurses. Other diagnoses will be found
requiring medical intervention, and many
patients need more careful clinical assess›
ment than a simple protocol provides.
Marshall and Rouse’s assumption that two
20 minute consultations by a practice nurse
are all that is needed to treat is wrong, so
their economic argument is flawed.
Their conclusion about statins and
angiotensin converting enzyme inhibitors
costing more, so strategies avoiding these
may allow more disease to be prevented is
odd. It would be actionable to omit a choles›
terol measurement on a high risk patient or
if a high level was found, negligent not to
treat. Avoiding them is not an option in the
real world.
This paper adds little to the subject
other than confusing people into thinking
there is a quick and cheap method of cutting
short the hard and expensive, but necessary,
work of finding all those at risk of heart dis›
ease and lengthening their lives.
Gill Tyerman general practitioner
Peter Tyerman general practitioner
Rotherham Road Surgery, Barnsley S71 1UT
Trefor J Roscoe general practice informatics tutor,
North Trent
Institute of General Practice, Northern General
Hospital, Sheffield S7 1AU
1 Marshall T, Rouse A. Resource implications and health
benefits of primary prevention strategies for cardiovas›
cular diseases in people aged 30›74: mathematical model›
ling study. BMJ 2002;325:197›202. (27 July.)
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Authors’ reply
Editor—Our principal conclusion has not
been challenged: authors of guidelines
should explicitly model the resource impli›
cations and health benefits of following their
recommendations. The table shows the
results of modelling using Tyerman et al’s
suggestions: 12 prescriptions a year, all
assessment and follow up by doctors, patient
assessment taking 1 hour, stabilisation and
follow up taking 2 hours over five years. A
practice that preselects 200 patients to assess
prevents 82% as much cardiovascular
disease at 57% of the cost.
Simvastatin costs more and is less effec›
tive than identifying and treating new
patients with aspirin and antihypertensive
drugs. Five years’ treatment with simvastatin
10 mg costs £1175. Five years of aspirin,
atenolol, and hydrochlorothiazide, is £718,
including staff costs. The relative risk of
cardiovascular disease with statin treatment
is 0.7, with aspirin and antihypertensive
drugs 0.6 (0.8×0.75=0.6). This will be
explored further in a future paper.
We agree that there is an unresolved
dilemma in cardiovascular prevention. A cli›
nician acting in the best interests of an indi›
vidual patient prescribes a statin; a clinician
acting in the best interests of the whole
practice population does not but employs a
practice nurse to find and treat more
patients. The former is consistent with the
clinician’s duty of care but is a poor preven›
tion policy. The latter is consistent with the
optimum use of public funds.
We can also model the implications of
Tyerman et al’s preference for prioritising
50 year olds over 70 year olds. For 50 and 70
year old men life expectancy is 25 years and
11 years, respectively, and cardiovascular
mortality (per 10 000) is 12 and 111.1 Per
10 000 people, cardiovascular disease there›
fore accounts for 312 and 1243 lost years of
life in 50 and 70 year old men. We therefore
can potentially add four times more years to
life in 70 year olds than in 50 year olds. This
is not necessarily irrational. Only a rational
decision maker who valued the life years of
50 year olds four times more than those of
70 year olds would prioritise the younger
men over the older ones.
We agree that information on smoking
should be included when calculating prior
risk estimates. This would improve the accu›
racy and efficiency of preselection. However,
risk factor recording is not universally accu›
rate,2 so we modelled our approach in a
practice with the bare minimum of
electronically recorded data.
With our preselection strategies, a
woman’s cardiovascular risk is equivalent to
that of a man 12 years her junior. A good
approximation of our preselection rankings
is obtained by assigning a ranking number
to every patient. For men it is their age, for
women their age minus 12. Patients are pri›
oritised for cardiovascular risk assessment
by their ranking number (highest number
first).
Tom Marshall lecturer
Andrew Rouse senior lecturer
Public Health and Epidemiology, University of
Birmingham, Birmingham B15 2TT
1 Office for National Statistics. Mortality data from England
and Wales in 2000. London: Stationery Office, 2000. (www.
statistics.gov.uk/statbase/Product.asp?vlnk=618&More=N;
accessed 2 August 2002.)
2 Mant J, Murphy M, Rose P, Vessey M. The accuracy of gen›
eral practitioner records of smoking and alcohol use: com›
parison with patient questionnaires. J Public Health Med
2000;22:198›201.
Risk:benefit ratio is important
in treating atopic dermatitis
Editor—Williams acknowledges the effi›
cacy of tacrolimus and pimecrolimus in
atopic dermatitis but subsequently his
editorial is negative and lacks any patient
perspective.1 The issue lies not in clinicians’
disembodied comparisons of efficacy but in
what treatment provides patients, or their
affected children, with the most acceptable
benefit:risk ratio.
Only 40% of patients with eczema are
reportedly satisfied with their treatment, and
work from Williams’s own department has
shown that in many cases using a topical
corticosteroid produces risks, especially of
skin thinning, which are unacceptably high
to the patients, resulting in non›compliance
and inadequate treatment.2
Patients’ fears about steroids can hardly
be dismissed as irrational, even though they
may be exaggerated. Far from being rare, the
risks of adverse events from the use of
steroids are directly related to the duration,
quantity, and potency of the steroid used.
Thus today’s patients are just as much at risk
as before unless they choose to endure the
misery of their condition and leave it under›
treated. The main fear which patients had
was of skin thinning. Topical tacrolimus and
pimecrolimus are free of this and other risks
associated with steroid use and offer a realis›
tic alternative of proved efficacy whatever
their potencies relative to each other or to
corticosteroids.
Although the editorial declares the use
of probiotics harmless, the long term risks of
using such strategies are currently unknown
and the subject of debate.3 Their safety has
not been tested on anything like the 13 000
included in the trials of tacrolimus and
pimecrolimus.
As with any new treatment, close moni›
toring will be mandatory, but longer term
studies with pimecrolimus and tacrolimus
show no clinically significant increase in
infections or skin cancers.4 5 Since the drugs
are non›mutagenic, are absorbed only
slightly, and do not permanently impair
primary immune responses, an increased risk
of cancer either topical or visceral is most
unlikely. It is of note that with over 40 years of
use of potent topical steroids—which not only
deplete cutaneous Langerhans cells but are
highly immunosuppressant as well as being
systemically absorbed—there is no evidence
that they predispose to cancer either cutane›
ous or systemic. These new drugs for atopic
dermatitis are welcomed by patients, parents,
and doctor as a wholly new treatment option
for this demoralising disease. They are the
first major advance in its management in half
a century.
B Roger Allen consultant dermatologist
Department of Dermatology, University Hospital,
Queen’s Medical Centre, Nottingham NG11 6QU
brallen1@aol.com
Thomas A Luger
Department of Dermatology, Westphalian
Wilhelms›University of Münster,
Von›Esmarch›Strasse 56, D›48149 Münster,
Germany
luger@uni›muenster.de
The authors have received funding from
Fujisawa and Novartis to advise on and carry out
clinical studies on tacrolimus and pimecrolimus.
1 Williams H. New treatments for atopic dermatitis. BMJ
2002;324:1533›4
2 Charman CR, Morris AD, Williams HC. Topical cortico›
steroid phobia in patients with atopic eczema. Br J Derm
2000;142:931›6.
3 Murch SH. Toll of allergy reduced by probiotics. Lancet
2001;357:1057›8.
4 Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra
A, et al. Efficacy and safety of pimecrolimus cream in the
long›term management of atopic dermatitis in children.
Pediatrics 2002;110:1›8.
5 Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM.
Long›term safety and efficacy of tacrolimus ointment for
the treatment of atopic dermatitis in children. J Am Acad
Dermatol 2001;44(suppl 1):S58›64.
Using evidence based tools to
manage chronic illness
Editor—Von Korff et al discussed how to
organise care for chronic illness.1 Since 1993
we have used evidence based care tools that
combine patients’ needs, values, and percep›
tions with scientifically valid patient based
assessments to measurably improve and
maintain health related quality of life.
We routinely use the functional health
assessment questionnaire (SF›36) and the
Zung depression, Beck anxiety, and
Epworth sleepiness scales. We integrate
these data with patient self care data
Resource implications and health consequences of cardiovascular disease prevention with Tyerman
et al’s suggestions
No of
patients
assessed
No of patients
eligible for any
drug treatment
Workload (h)
Benefit: CVD events
prevented per 5 years
Cost per 5 years
(£)Assessment clinic Follow up clinic
100 75 100 50 6.7 145 735
200 113 200 75 9.2 222 967
300 135 300 90 10.3 269 687
400 147 400 98 10.8 301 094
939 163 939 108 11.2 389 099
CVD=cardiovascular disease.
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(reports on weekly exercise, self monitoring
of blood pressure, breast self examination,
seat belt use while driving, etc) and
condition specific data (glycated haemo›
globin concentration, cardiac risk index,
T scores on bone densitometry, ejection
fraction on cardiac echocardiography, etc).
The process is appealing in both
prepaid and self payment health care
because the health strategy can be tailored,
focusing on the patient’s concerns and
needs first and including any remaining
concerns from practitioners. Clients enter
the integrative health process through an
initial integrative health consultation. The
SF›36 is used as the baseline measure of
quality of life. It contains scores summaris›
ing both physical and mental function and
eight subscales (physical functioning, role
physical limitations, bodily pain, general
health perception, vitality, social function,
role emotional limitations, and mental
health).
A standardised interview identifies
patients’ perception of why they are
underfunctioning as well as their perception
of what is necessary to bring their experi›
ence of health to a place of excellence. We
keep the clients engaged by addressing both
their pain and their hopes simultaneously in
one strategic plan.
We are in the process of refining our col›
laborative methods for displaying trends
during telephone conferences with a group
of focused, local health practitioners and,
when necessary, the patient and a family
member. Such a care conference would
allow evaluation of trends and modification
of the strategic plan as needed. Our
principal challenge has been technological.
These methods will be widely accessible
when simple communication, assessment,
and reporting technology becomes practi›
cal, affordable, and available to busy
practitioners.
Dwana M Bush family physician
Integrative Health Institute/Atlanta Family
Medicine, Atlanta, GA 30342, USA
dbush@integrativehealth.com
1 Von Korff M, Glasgow RE, Sharpe M. ABC of psychologi›
cal medicine: organising care for chronic illness. BMJ
2002;325:92›4. (13 July.)
Criticism of new German
chronic disease management
is unfair
Editor—Tuffs’ news item on the new
chronic disease management programmes
in Germany is misleading.1
The new programmes have arisen from
economic analysis showing the importance
of ensuring that health insurance funds
should not continue to be penalised
financially when they have large numbers of
patients with chronic diseases.
The economic rationale for these pro›
grammes is not simply to fund deficits.
There will be no extra money put into the
system. Instead the existing risk adjustment
strategy will take the higher costs for
patients with chronic disease (initially type 2
diabetes and breast cancer) directly into
account. Ultimately the government hopes
to implement a new risk adjustment model
that takes account of all pre›existing
morbidity.
The federal government’s new pro›
grammes have arisen after the latest report
of the Sachverständigenrat (the govern›
ment’s advisory council) using data from
the Organisation for Economic Coopera›
tion and Development (OECD). Germany
has the highest health expenditure in
Europe with questionable quality of care.
The programmes aim to eliminate overuse,
underuse, and misuse of care.
The German Medical Society, statutory
health insurance physicians, the hospitals
society, and health insurance companies
participated in the working group and the
political committee that recommended
these programmes to the government. The
physicians could appoint their own experts
and agree on all aspects of the programmes.
All agreed, except for the hospitals society,
which opposed requiring an evidence base
for specific drugs. Thus it is hard to
understand why the German Medical
Society should have agreed on programmes
that its president, Jörg›Dietrich Hoppe, now
considers meet only minimal standards.1
Condemning the new disease manage›
ment programmes as inferior to routine
care is pure polemic. For the first time in
German medicine, such programmes have
been built on a solid basis of evidence based
medicine, combining the best available
evidence with clinical expertise.
We conclude that the doctors’ opposi›
tion to these programmes results from the
deep cultural shock felt by those who
thought that medical experts could never
come into conflict with evidence based
medicine, which for the first time has
become an integral part of official govern›
mental programmes. Physicians’ representa›
tives are also not amused that the health
insurance companies showed their willing›
ness to become players rather than just pay›
ers in the development of these new disease
management programmes.
These programmes will be updated
regularly and must go through a tough
process of certification and evaluation
before they can become part of the risk
adjustment mechanism. We strongly believe
that they will enable us to overcome the
important obstacles that we presently face in
providing integrated care for people with
chronic diseases.
Norbert Schmacke head
Norbert.Schmacke@bv.aok.de
Jörg Lauterberg vice head
Medical Department, Federal Association of the
Local Health Funds (Bonn›Germany), Kortrijker
Strasse 1, D›53177 Bonn, Germany
1 Tuffs A. Chronic disease management programmes are
criticised by doctors. BMJ 2002;325:356. (17 August.)
Patient education is not a
treatment modality
Editor—In their editorial Riemsma et al
treat patient education in rheumatoid
arthritis as a treatment modality, showing
that it produces some minor improvements
in a series of outcome measures.1
I have some reservations about treating
patient education in this way. Providing
people with medical conditions with infor›
mation about their options is now an ethical
requirement so that they can give informed
consent. In such an uncertain and poten›
tially life threatening and crippling condi›
tion as rheumatoid arthritis, health provid›
ers must supply as much information as
patients require so that they can make the
many decisions about their management in
an informed way. It is an obligation, not a
treatment modality, although knowledge
can improve coping mechanisms and help
internalise control, which both have benefi›
cial long term effects.
It is also neither efficient nor effective a
use of resources to prescribe all patients with
a chronic disease such as rheumatoid arthri›
tis counselling or behaviour modification.
Armed with the facts from education
sessions, many patients work out their own
ways of coping and managing their condi›
tion, and this will not be improved by either
counselling or behaviour modification.
Some patients do need counselling to help
them accept their condition and its implica›
tions and to plan for the future. Others with
adverse health beliefs and dysfunctional
behaviours will benefit from behaviour
modification.
Thus I do not believe that judging these
modalities by their effect on every member
of a population with rheumatoid arthritis
provides a true measure of their worth.
Information giving is an ethical obligation.
The indications for counselling and behav›
ioural modification can be defined. It is in
this group that the placebo clinical trials
should be performed.
In this age of cost effectiveness, ethical
obligations and modalities that are effective
when targeted properly must not be cast
away because they are not as effective as
drug treatment in a population. They are
designed for a different job. Every patient
with rheumatoid arthritis would be given a
hip replacement by this reckoning, for
example.
Jeremy J Jones consultant rheumatologist
Ysbyty Gwynedd, Bangor, Gwynedd LL57 2PW
jeremy.jones@nww›tr.wales.nhs.uk
1 Riemsma RP, Taal E, Kirwan JR, Rasker JJ. Patient
education programmes for adults with rheumatoid arthri›
tis. BMJ 2002;325:558›9. (14 September.)
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